Nuwellis Announces Aquadex Software Update
Rhea-AI Summary
Nuwellis (NASDAQ: NUWE) released a software update for the Aquadex SmartFlow ultrafiltration platform on April 21, 2026. The update reduces ultrafiltration step size from 10 mL/hr to 5 mL/hr, adds a refined blood flow algorithm to reduce nuisance alarms, improves clotting visibility, and expands hourly therapy logs. The update targets improved usability and more precise fluid management for pediatric patients and is available to existing customers at no cost via standard deployment with field support.
Positive
- Ultrafiltration step size reduced to 5 mL/hr from 10 mL/hr
- Update available to existing customers at no cost
- Refined blood flow algorithm aimed to reduce nuisance alarms
- Expanded hourly data log with additional therapy parameters
Negative
- None.
News Market Reaction – NUWE
On the day this news was published, NUWE declined 0.86%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NUWE was down 1.69% with momentum peers VTAK and BJDX also down (median move about -3.7%), indicating broader sector pressure alongside this company-specific product update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 16 | Commercial hires | Positive | -2.9% | Rehiring three former employees to accelerate Aquadex commercial and clinical momentum. |
| Apr 09 | IR engagement | Positive | +0.0% | Engaged CORE IR for PR, shareholder communications, and social media support. |
| Apr 07 | Territory expansion | Positive | +3.7% | Created dedicated South Texas commercial territory to strengthen hospital engagement. |
| Mar 31 | Pediatric milestone | Positive | +0.0% | Pediatric category reached ~50% of U.S. revenue across 47 centers in 2025. |
| Mar 17 | Acquisition close | Positive | -8.5% | Completed Rendiatech acquisition to add automated continuous kidney function monitoring. |
Recent positive corporate updates often saw flat or negative next-day moves, including hires and acquisitions.
Over the last few months, Nuwellis has focused on expanding and enhancing its Aquadex platform and commercial reach. On Mar 17, 2026, it completed the Rendiatech acquisition to add automated kidney monitoring. By Mar 31, 2026, pediatrics had become roughly 50% of U.S. revenue across 47 centers. Early April announcements added a South Texas territory and new IR support, and on Apr 16, 2026 the company rehired three experienced team members. Today’s Aquadex software update fits this pattern of product and pediatric-focused optimization.
Regulatory & Risk Context
An effective S-3 resale registration filed on Feb 3, 2026 covers up to 4,279,325 warrant-related shares. Nuwellis will not sell shares directly but may receive up to $28 million in cash if all registered warrants are exercised.
Market Pulse Summary
This announcement highlights an Aquadex SmartFlow software update aimed at more precise fluid management, especially for pediatric patients, by reducing ultrafiltration step size to 5 mL/hr from 10 mL/hr. It complements Nuwellis’ recent focus on pediatrics and platform enhancements following the Rendiatech acquisition. Against a backdrop of going-concern disclosure and an effective resale registration, investors may watch for evidence that these usability upgrades drive higher utilization and pediatric growth within the existing customer base.
Key Terms
ultrafiltration medical
cardiorenal medical
pediatric medical
AI-generated analysis. Not financial advice.
New release enhances usability and delivers more precise fluid management for pediatric patients
MINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex SmartFlow® ultrafiltration platform. The update is designed to improve usability, streamline clinical workflow, and enhance overall user experience.
A key feature of the release is a more precise ultrafiltration adjustment capability, reducing the step size to 5 mL/hr from 10 mL/hr. This advancement is particularly important in pediatric care, where small-volume fluid shifts can have a significant clinical impact.
“The Aquadex software update reflects our commitment to continuous improvement driven by customer feedback and clinical need,” said Nuwellis’ CEO John Erb. “This release provides clinicians with greater control over fluid management – especially in pediatric patients, which represents our largest and fastest-growing customer category – while also making the system easier to use in demanding care environments.”
The update also includes enhancements aimed at improving ease-of-use of the device and therapy visibility, particularly for nursing staff managing day-to-day treatment. Key updates include:
- Refined blood flow algorithm designed to reduce nuisance alarms and improve flow stability;
- Enhanced blood flow resistance graph to provide earlier indication of potential filter clotting ; and
- Expanded hourly data log with additional therapy parameters to support clinical monitoring and documentation.
The software update is available to existing customers at no cost and can be deployed through standard update processes with support from Nuwellis’ field and service teams.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
